Tremelimumab structure
|
Common Name | Tremelimumab | ||
---|---|---|---|---|
CAS Number | 745013-59-6 | Molecular Weight | N/A | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | N/A | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of TremelimumabTremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
Name | Tremelimumab |
---|---|
Synonym | More Synonyms |
Description | Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 (CTLA-4) and can be used for metastatic melanoma research[1]. |
---|---|
Related Catalog | |
In Vitro | Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans[1]. Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner[1]. Tremelimumab enhances the IL-2 production in T-cells[1]. |
References |
Storage condition | 2-8°C |
---|
Ticilimumab |
CP-675206 |